A nanoemulsion targeting adipose hypertrophy and hyperplasia shows anti-obesity efficiency in female mice

Yichao Lu,Zhenyu Luo,Huanli Zhou,Yingying Shi,Ying Zhu,Xuemeng Guo,Jiaxin Huang,Junlei Zhang,Xu Liu,Sijie Wang,Xinyu Shan,Hang Yin,Yongzhong Du,Qingpo Li,Jian You,Lihua Luo

DOI: https://doi.org/10.1038/s41467-023-44416-3

IF: 16.6

2024-01-02

Nature Communications

Abstract:Abstract Obesity often leads to severe medical complications. However, existing FDA-approved medications to combat obesity have limited effectiveness in reducing adiposity and often cause side effects. These medications primarily act on the central nervous system or disrupt fat absorption through the gastrointestinal tract. Adipose tissue enlargement involves adipose hyperplasia and hypertrophy, both of which correlate with increased reactive oxygen species (ROS) and hyperactivated X-box binding protein 1 (XBP1) in (pre)adipocytes. In this study, we demonstrate that KT-NE, a nanoemulsion loaded with the XBP1 inhibitor KIRA6 and α-Tocopherol, simultaneously alleviates aberrant endoplasmic reticulum stress and oxidative stress in (pre)adipocytes. As a result, KT-NE significantly inhibits abnormal adipogenic differentiation, reduces lipid droplet accumulation, restricts lipid droplet transfer, impedes obesity progression, and lowers the risk of obesity-associated non-alcoholic fatty liver disease in female mice with obesity. Furthermore, diverse administration routes of KT-NE impact its in vivo biodistribution and contribute to localized and/or systemic anti-obesity effectiveness.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the effective treatment of obesity. Specifically, the existing FDA - approved anti - obesity drugs have limited effects in reducing fat accumulation and are often accompanied by side effects. These drugs mainly function by acting on the central nervous system or interfering with fat absorption in the gastrointestinal tract. However, these methods have not effectively and safely achieved systemic anti - obesity effects and local fat - reduction effects. Therefore, researchers have proposed a new treatment method - KT - NE nano - emulsion, aiming to simultaneously relieve endoplasmic reticulum stress and oxidative stress, thereby inhibiting abnormal adipogenic differentiation, reducing lipid droplet accumulation, limiting lipid droplet transfer, hindering the progress of obesity, and reducing the risk of non - alcoholic fatty liver disease associated with obesity.

KT - NE is a nano - emulsion loaded with the XBP1 inhibitor KIRA6 and α - tocopherol, which can intervene in the overactive XBP1 and excessive ROS in obese tissues. In this way, KT - NE can not only inhibit the excessive proliferation (hypertrophy) and neogenesis (hyperplasia) of adipocytes, but also reduce the transfer of lipid droplets, thereby preventing the development of obesity. In addition, different administration routes of KT - NE have an impact on its distribution in the body, which helps to achieve local and/or systemic anti - obesity effects. The main goal of the study is to verify the anti - obesity efficiency of KT - NE in a female mouse model.